PulseSight tees up first human PST-611 data in geographic atrophy: full analysis
PulseSight Therapeutics is moving its lead retinal program into public view, saying it has completed the last-patient, last-visit milestone in the Phase I PST-611-CT1 trial and will present first-in-human data on PST-611 for dry age-related macular degeneration, specifically geographic atrophy, at ARVO 2026 in Denver. The study is the company’s first clinical readout for PST-611, a non-viral gene therapy candidate designed to express transferrin. (globenewswire.com)
The program has been building toward this point since at least January 2025, when PulseSight said it had submitted a Clinical Trial Authorization application to France’s ANSM, followed by ANSM clearance in June 2025. At that stage, the company described PST-611-CT1 as a first-in-human, single-ascending-dose study in six to 12 patients intended to confirm safety and tolerability and identify a dose for Phase II proof-of-concept work. The first patient was dosed in July 2025, and by April 23, 2026, the company said follow-up had been completed for all treated patients. (pulsesight.com)
The latest company update says six patients were treated over the past year in two successive cohorts at two dose levels, with investigators in Paris and Grenoble. Results are scheduled for presentation by Professor Francine Behar-Cohen on May 7, 2026, in an ARVO session on diabetic retinopathy and related disorders, under abstract #5926. PulseSight has framed PST-611 as a first-in-class candidate for geographic atrophy that targets iron dysregulation, which the company says contributes to inflammation, oxidative stress, ferroptosis, and retinal cell death in dry AMD. (globenewswire.com)
What makes the program stand out is the platform as much as the payload. PulseSight says PST-611 uses electro-transfection to deliver a DNA plasmid into the ciliary muscle, which then acts as a local “biofactory” producing therapeutic protein that can reach the retina. In preclinical work highlighted by the company and trade coverage, transferrin-based therapy was associated with protection of photoreceptors and retinal pigment epithelium cells, preservation of visual function, and a favorable safety profile in animal models. A 2020 paper on the underlying non-viral transferrin gene therapy approach also reported sustained intraocular production of transferrin in animal models, supporting the company’s durability argument. (globenewswire.com)
Independent expert reaction was limited ahead of the presentation, but industry coverage suggests the ARVO readout is being watched as an early test of whether non-viral ocular gene therapy can show an acceptable safety profile in geographic atrophy. The Ophthalmologist noted that the small sample size reflects the early-stage nature of the study and said observers will be looking for both initial safety signals and any early hints of biologic activity as the company prepares for Phase IIa development. Retinal Physician similarly described PST-611 as part of a growing wave of gene-based approaches for geographic atrophy. (theophthalmologist.com)
Why it matters: While this is a human biotech story, it has broader relevance for veterinary professionals following translational ophthalmology and advanced therapeutics. Retinal disease remains an area where durable local treatment, reduced injection burden, and safer delivery platforms are attractive across species. PulseSight’s approach also reflects a wider industry push beyond viral vectors, using targeted tissue delivery and in vivo protein production to try to extend treatment effect while managing tolerability. If the Phase I data are clean, it could strengthen interest in non-viral ocular gene delivery as a platform concept, not just a single-asset story. (globenewswire.com)
There’s also a market context behind the attention. Geographic atrophy remains a high-unmet-need condition despite recent progress in slowing lesion growth with complement-targeting drugs, and developers continue to look for approaches that could be more durable or mechanistically differentiated. PulseSight has already raised Series A funding to support Phase I and prepare for a Phase IIa trial, underscoring that investors see enough promise in the biology and delivery platform to keep the program moving. (pulsesight.com)
What to watch: The immediate catalyst is the ARVO 2026 presentation on May 7, 2026; after that, the main questions will be whether the safety profile supports dose selection, whether any early efficacy or biomarker signals emerge, and how quickly PulseSight can move into the planned Phase IIa study. (globenewswire.com)